The muscular dystrophies are generally characterised by progressive skeleta
l muscle wasting and weakness. Duchenne muscular dystrophy (DMD), an X-link
ed disorder, is the most severe of all the dystrophies and is caused by a v
ariety of mutations and deletions in the dystrophin gene. In the absence of
dystrophin expression, the skeletal muscles of boys with DMD undergo conti
nuous cycles of degeneration and regeneration of muscle fibres that lead to
a progressive wasting of the skeletal muscles. At age 10 years, DMD patien
ts have only 25% of the muscle mass of healthy children and the functional
burden on their weakened muscles is too great for normal ambulation well be
fore this time. The): become dependent on a wheelchair before their early t
eens and die of respiratory or heart failure by their early 20's. There is
a profound need for therapeutic intervention strategies that aim to cure or
ameliorate the dystrophic condition and improve the quality of life for th
ese patients. Therapeutic approaches for muscular dystrophy fall into two c
lasses: those chat attempt to ameliorate the dystrophic condition through p
harmacological interventions, or those that attempt to overcome the gene de
fect. The greatest likelihood of a cure for DMD and other muscular dystroph
ies will eventually be derived from gene therapy. However, problems continu
e to plague this research, including: the limitation of the spread of expre
ssion from injection sites in the muscle, the longevity of expression, the
need for systemic delivery, vector design and carrying capacity, and diffic
ulties with immunosuppression. Sadly, until these techniques are perfected,
boys with DMD will die and patients with other less severe neuromuscular c
onditions will continue to lose muscle mass and function. This review exami
nes recent (1997 - 2000) patents on novel therapies for muscular dystrophy
and evaluates their potential for ameliorating muscle wasting and/or improv
ing muscle function.